Literature DB >> 16762725

Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments.

Karin Schreiber1, Donald A Rowley, Gert Riethmüller, Hans Schreiber.   

Abstract

Experimental research on the immune response to transplanted tumors has led to pioneering discoveries that laid many of the foundations for the current field of immunology. Experimental research in oncology has proven that murine and human tumors have antigens that are truly cancer specific. This article discusses research investigating how can antigens on cancer cells be used to help eradicate cancer.

Entities:  

Mesh：

Year:  2006        PMID： 16762725     DOI： 10.1016/j.hoc.2006.03.001

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  26 in total

1.  Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system.

Authors:  Metamia Ciampricotti; Cheei-Sing Hau; Chris W Doornebal; Jos Jonkers; Karin E de Visser
Journal:  Nat Med       Date:  2012-03-06       Impact factor: 53.440

Review 2.  Targeting cancer-specific mutations by T cell receptor gene therapy.

Authors:  Thomas Blankenstein; Matthias Leisegang; Wolfgang Uckert; Hans Schreiber
Journal:  Curr Opin Immunol       Date:  2015-02-27       Impact factor: 7.486

3.  Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer.

Authors:  David C Binder; Boris Engels; Ainhoa Arina; Ping Yu; James M Slauch; Yang-Xin Fu; Theodore Karrison; Byron Burnette; Christian Idel; Ming Zhao; Robert M Hoffman; David H Munn; Donald A Rowley; Hans Schreiber
Journal:  Cancer Immunol Res       Date:  2013-08       Impact factor: 11.151

4.  Tumour ischaemia by interferon-γ resembles physiological blood vessel regression.

Authors:  Thomas Kammertoens; Christian Friese; Ainhoa Arina; Christian Idel; Dana Briesemeister; Michael Rothe; Andranik Ivanov; Anna Szymborska; Giannino Patone; Severine Kunz; Daniel Sommermeyer; Boris Engels; Matthias Leisegang; Ana Textor; Hans Joerg Fehling; Marcus Fruttiger; Michael Lohoff; Andreas Herrmann; Hua Yu; Ralph Weichselbaum; Wolfgang Uckert; Norbert Hübner; Holger Gerhardt; Dieter Beule; Hans Schreiber; Thomas Blankenstein
Journal:  Nature       Date:  2017-04-26       Impact factor: 49.962

5.  Ultrasound-stimulated drug delivery for treatment of residual disease after incomplete resection of head and neck cancer.

Authors:  Anna G Sorace; Melissa Korb; Jason M Warram; Heidi Umphrey; Kurt R Zinn; Eben Rosenthal; Kenneth Hoyt
Journal:  Ultrasound Med Biol       Date:  2014-01-10       Impact factor: 2.998

6.  A positive-margin resection model recreates the postsurgical tumor microenvironment and is a reliable model for adjuvant therapy evaluation.

Authors:  Jarrod D Predina; Brendan Judy; Zvi G Fridlender; Louis A Aliperti; Brian Madajewski; Veena Kapoor; Guanjun Cheng; Jon Quatromoni; Olugbenga Okusanya; Sunil Singhal
Journal:  Cancer Biol Ther       Date:  2012-05-23       Impact factor: 4.742

7.  Progression of cancer from indolent to aggressive despite antigen retention and increased expression of interferon-gamma inducible genes.

Authors:  Terry H Wu; Karin Schreiber; Ainhoa Arina; Nikolai N Khodarev; Elena V Efimova; Donald A Rowley; Ralph R Weichselbaum; Hans Schreiber
Journal:  Cancer Immun       Date:  2011-06-30

8.  CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors.

Authors:  Angela M Tatum; Lawrence M Mylin; Susan J Bender; Matthew A Fischer; Beth A Vigliotti; M Judith Tevethia; Satvir S Tevethia; Todd D Schell
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

9.  Fas expression by tumor stroma is required for cancer eradication.

Authors:  Joanna J Listopad; Thomas Kammertoens; Kathleen Anders; Bjoern Silkenstedt; Gerald Willimsky; Karin Schmidt; Anja A Kuehl; Christoph Loddenkemper; Thomas Blankenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-22       Impact factor: 11.205

Review 10.  Personalized immune-interception of cancer and the battle of two adaptive systems--when is the time right?

Authors:  Madhav V Dhodapkar
Journal:  Cancer Prev Res (Phila)       Date:  2013-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.